Thursday – Clinical Track 1A

Full Name(Required)
Enter your first and last names as you would like them to appear on your certificates.
Enter the email you used to register for TOXINS 2022.

Please evaluate the speakers for Clinical Track 1A – Adult Spasticity I

Topic and Speaker(s)
ExcellentGoodFairPoor
What's New? BoNT Clinical Trial Update: Adult Spasticity
Gerard Francisco (USA)
Gait Pattern Recognition and Muscle Selection for BoNT Injections
Alberto Esquenazi (USA)
What Are We Missing? It’s More Than Injections
Laura Wiggs (USA)
What Are the Early Risk Factors for Disabling Spasticity—Does BoNT Treatment Reduce the Risk Effectively?
Anthony Ward (UK)
YesNo
What's New? BoNT Clinical Trial Update: Adult Spasticity
Gerard Francisco (USA)
Gait Pattern Recognition and Muscle Selection for BoNT Injections
Alberto Esquenazi (USA)
What Are We Missing? It’s More Than Injections
Laura Wiggs (USA)
What Are the Early Risk Factors for Disabling Spasticity—Does BoNT Treatment Reduce the Risk Effectively?
Anthony Ward (UK)
YesNo
What's New? BoNT Clinical Trial Update: Adult Spasticity
Gerard Francisco (USA)
Gait Pattern Recognition and Muscle Selection for BoNT Injections
Alberto Esquenazi (USA)
What Are We Missing? It’s More Than Injections
Laura Wiggs (USA)
What Are the Early Risk Factors for Disabling Spasticity—Does BoNT Treatment Reduce the Risk Effectively?
Anthony Ward (UK)
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care

Join Our Mailing List

Click here to sign up, and then manage your subscription.